1. Introduction {#sec0005}
===============

Acrylamide (AA) is a monomer used in the manufacture of polymers for mining, oil and natural gas processing, paper manufacture, waste processing, hospital laboratories, among other uses. Adverse health effects from worker exposure to AA have been extensively studied [@bib0220]. No adverse effects have been reported with daily human exposure up to 2.1 mg/kg/day [@bib0095]. Exposure to AA in foodstuffs has become a worldwide concern because of its generation in a variety of carbohydrate rich foods when these are cooked at temperatures exceeding 120 °C. At these temperatures, AA is made from the Maillard reaction of sugars with asparagine residues [@bib0120], [@bib0275].

The World Health Organization (WHO) and Food and Agriculture Organization [@bib0110], the Environmental Protection Agency [@bib0090], and the European Food Safety Authority [@bib0080] have classified AA as a "probable human carcinogen" by virtue of its conversion to glycidamide, as the ultimate carcinogen in rodents. *In vivo*, AA is metabolized by CYP 2E1 to glycidamide (an epoxide), which also is very reactive toward nucleophiles and has been implicated in adduct formation at active site cysteines of proteins and the amino terminus of hemoglobin and also with nucleic acids [@bib0120], [@bib0235]. Only a portion of the AA gets converted to glycidamide. The classification as a probable human carcinogen is based primarily upon reproducible carcinogenicity studies in Fischer rats [@bib0010], [@bib0130], [@bib0170]. Tumors were observed in the mammary gland (fibroadenomas), thyroid (follicular tumors) and tunica vaginalis testes in rats [@bib0010], [@bib0130], [@bib0165]. These tumor sites have well documented rat-specific modes of action, which are not relevant to humans [@bib0015], [@bib0155], [@bib0280], [@bib0295].

Thyroid follicular tumors can arise in rats specifically from chemical disturbance of thyroid-pituitary homeostasis, or from a combination of genotoxicity and hormonal alterations. External factors that change thyroid hormone metabolism result in a marked change in thyroid behavior in rats [@bib0180]. AA treatment for 7, 14 or 28 days results in increased mitotic figures and Dfigures and DNA synthesis in the thyroids of Fischer rats [@bib0215]. The Fischer rat has a unique hormonal milieu that may be responsible for these tumors. However, specific changes in thyroid transcriptomics have yet to be documented. It has been suggested that alteration of the dopamine receptor is responsible for the change in thyroid metabolism [@bib0325]. AA also causes oxidative stress in rats [@bib0360] and the thyroid has a very high oxidation level [@bib0360], [@bib0365].

AA is mutagenic in rats and mice [@bib0060]. This mutagenic profile does not fit the pattern of tumors observed in Fischer rats, as the specificity cannot be explained [@bib0135], [@bib0260], [@bib0325], [@bib0370]. AA is a very weak carcinogen and mutagen [@bib0370]. Since mutagenicity is the regulatory default assumption as a mechanism for carcinogenicity, use of other mechanistic data for regulatory purposes has been limited. In contrast to the Fischer rat, the only significant tumors observed in male Wistar rats were in the thyroid gland [@bib0255]. While thyroid tumors in rats are not considered to be relevant to humans, mechanisms for genotoxicity in the thyroid still represent a possible significant risk. This study was designed to build upon the large volume of data published to date about AA exposure of rats to determine whether tumors formed in the thyroid after chronic exposure to AA were produced only through a genotoxic component.

The research conducted here determines the effect of AA on gene expression in weanling Wistar rat thyroids following in utero exposure to a carcinogenic dose of AA. This research is intended to differentiate between DNA reactivity, oxidative stress and direct action on hormone receptors. A transcriptomics approach (microarrays and bioinformatics) was used to investigate changes in gene expression and the association with physiological responses (changes in plasma hormone levels) in rats treated with AA from gestational day 6 to post-natal day 35. We hypothesized that 3 mg AA/Kg bw/day exposure would produce changes in plasma hormone levels associated with key genes and biochemical pathways involved with molecular actions of AA.

2. Materials and methods {#sec0010}
========================

2.1. Test material {#sec0015}
------------------

AA (C3H3NO, CAS no 79-06-1, 1,2-propenamide; \>99.9% pure; Sigma Aldrich) was dissolved in tap water and evaluated for stability at room temperature at 6, 13, 20, and 27 test days after preparation. Recovery ranged from 96.9% to 102.6%.

2.2. Animal exposures {#sec0020}
---------------------

The methods used to conduct this study have been previously published [@bib0255]. The *in vivo* phase of this study was conducted under GLP guidelines and was externally audited. It was approved by the responsible local government office according to the German animal welfare law "Tierschutzgesetz" (TierSchG). AA solutions were prepared weekly and concentrations were adjusted for body weight. Water bottles were changed weekly. AA concentration in the drinking water was determined at test week 4 and 10.

Sperm positive female Wistar Han™/RccHan™:WIST rats were obtained from Harlan Laboratories GmbH, Serumweg 48, 27324 Eystrup, Germany in multiple deliveries. At gestation day 6, dams were provided AA in their drinking water. Exposures continued in F1 offspring through postnatal day (pnd) 35 ± 3. Rats were housed 1 per cage in MACROLON cages with granulated wood bedding (Brandenburg, 49424 Goldenstedt/Arkeburg). Animal rooms were alternately lit (about 150 lx at approximately 1.50 m room height) and darkened in a 12-hour lighting cycle. Cage side observations were conducted twice per day during the week and once per day on weekends.

On day 4 after birth, the weights of the pups were determined. The size of each litter was adjusted by eliminating extra pups to yield, as nearly as possible, five males and five females per litter and remaining animals remained with the dams until day 21 of lactation (weaning). On lactation day 21, the F~1~ animals were randomized using a computer randomization program to assign the animals to the subsets within each group.

A separate cohort of the animals was allowed to continue on the same regimen for two years. At the end of the two years, mammary gland fibroadenomas were identified in females and thyroid follicular cell tumors were identified in both sexes [@bib0255].

2.3. Plasma TSH, T3 and T4 analysis {#sec0025}
-----------------------------------

On pnd 35 ± 3, at approximately 10 AM and 10 PM, respectively, as much blood as possible was withdrawn from 5 male and 5 female F1 rats/dose. The thyroids were removed and frozen. Blood samples were divided into 5 aliquots. Four aliquots of at least 75 μL were frozen and stored at −20 °C. Two aliquots were analyzed using the rat pituitary panel from Millipore for adrenocorticotropic hormone (ACTH), brain-derived neurotrophic factor (BDNF), growth hormone (GH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin. Then two aliquots were analyzed using the rat thyroid milliplex kit from Millipore for T3, T4 and TSH.

2.4. Extraction of total RNA and RNA quality control {#sec0030}
----------------------------------------------------

Total RNA was extracted from the thyroid gland of rats (n = 4; 4 controls and 4 AA-treated per tissue) using RNA STAT-60 reagent (Tel-Test Inc., Friendswood, TX, USA) according to the manufacturer's instructions. A total of 500 ng of RNA was DNase-treated with Turbo DNA-free (Ambion Austin, TX) following the manufacturer's protocol. RNA quantity for microarray analysis was measured using the NanoDrop ND-1000 (Nanodrop Technologies, Wilmington, DE) and RNA quality was evaluated using the Agilent 2100 BioAnalyzer with the RNA 6000 Nanochip. RNA integrity values (RIN) were \>8.0 for all samples used in the analysis. Total RNA was used for microarray analysis and real-time quantitative PCR (qPCR).

2.5. Microarray analysis {#sec0035}
------------------------

Gene expression patterns of thyroid samples were identified using the Rat V1 8 × 60 K oligonucleotide microarray manufactured by Agilent (Palo Alto, CA, USA). 100 ng of total RNA per sample (n = 4 biological replicates for each condition) were used for the analysis following the manufacturer's kits and protocols (Agilent Low input Quick-amp labeling kit one color; Agilent, Santa Clara, CA, USA). All samples used for microarrays contained a specific activity \>9.0 pmol Cy3/ml and amounts were adjusted to a final mass of 600 ng. Microarrays were kept in the dark until scanning using an Agilent G2505B microarray scanner. Data extraction was performed using Agilent Feature Extraction software (v 9.5). All microarrays were submitted to NCBI's Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) with accession number (GSE 62026). We had technical issues with samples from male rats collected in the morning and for this reason, these results are not being presented here.

2.6. Bioinformatics {#sec0040}
-------------------

The microarray data were analyzed independently by two different groups using JMP Genomics v5 (SAS, Cary, NC, USA) and by open source R-based software packages. The microarrays were performed in two different batches, one year apart, and it was impossible to analyze both batches in one ANOVA because of significant batch effects. Thus, each of the batches was analyzed separately and comparisons at the pathway level were possible between the two batches.

In JMP Genomics, raw expression data were log2-transformed and all control and non-uniform spots were removed prior to the final analysis. All probe responses per gene were averaged before using median normalization. One-way ANOVA was used to find genes that were significantly altered (p \< 0.05; fold change greater than ±1.2). The list of genes from the ANOVA was subjected to hierarchical clustering for each batch of arrays independently. The arrays were also analyzed by other non-parametric algorithms including Gene Set Enrichment Analysis (GSEA) [@bib0345] and Fischer Exact Test with the Sub-Network Enrichment Analysis (SNEA) [@bib0200] available through PathwayStudio™ (Elsevier Inc., Philadelphia, PA, USA), described in more detail below.

The second analysis used R-based software packages in a step-wise process consisting of a quality assessment of the array data, processing of the arrays for background correction and group normalization, unsupervised clustering, and class comparison for differential expression. The software components required to execute the source code include the following: (1) R environment for statistical programming (R package Limma) [@bib0335]; (2) Several package libraries from BioConductor [@bib0175]; (3) R markdown text formatting system; and (4) Knitr engine for dynamic report generation with R. Statistical criteria for identification of differentially expressed genes were false discovery rate (FDR) adjusted P\* \< 0.05 and fold change greater than 1.5. Based upon these filter criteria no differential gene expression was observed between animals exposed to AA and controls. Further analysis with FDR adjusted P\* \< 0.10 resulted in 1 gene being differentially expressed between AA treated animals and controls (Slc35b1, log FC = 1.6, P\* = 0.05, solute carrier family 35, member B1).

2.7. PathwayStudio™ analysis {#sec0045}
----------------------------

Pathway Studio™ V9 (operating with the ResNet 9.0 database) was used to identify molecular pathways associated with chronic toxicity of AA. Specifically two datasets were generated using (1) Fisher's Exact Test with (*p*-value \< 0.05) and SNEA and (2) GSEA, using the Kolmogorov-Smirnov test (p \< 0.05) [@bib0200], [@bib0345]. GSEA is an analytical method used to evaluate microarray data at the level of gene sets, which are defined based on prior biological knowledge of gene ontology and curated pathways [@bib0200], [@bib0345].

2.8. Quantitative real-time PCR (qPCR) {#sec0050}
--------------------------------------

Quantitative reverse transcriptase polymerase chain reaction (qPCR) was performed in order to confirm some of the results of differential gene expression identified by microarray analysis. We selected five different genes for the morning animals and five for the night animals and used TaqMan probes designed and validated by Applied Biosystems (Foster City, CA, USA). Gene symbols and ID of the TaqMan assays used are identified in [Table 1](#tbl0005){ref-type="table"}.Table 1Genes selected for confirmation by qPCR.Table 1Night group genesGen bank AccessionGene NameGene SymbolID[a](#tblfn0005){ref-type="table-fn"}[NM_022303](ncbi-n:NM_022303){#intr0005}Caspase recruitment domain family, member 9Card9Rn00673582_m1[NM_012547](ncbi-n:NM_012547){#intr0010}Dopamine receptor D2Drd2Rn00561126_m1[NM_080906](ncbi-n:NM_080906){#intr0015}DNA-damage-inducible transcript 4Ddit4Rn01433735_g1[NM_019353](ncbi-n:NM_019353){#intr0020}Thyroid peroxidaseTpoRn00571159_m1NM_001009623Tumor necrosis factor (ligand) superfamily, member 13Tnfsf13Rn01467490_g1Morning group gene[NM_053749](ncbi-n:NM_053749){#intr0025}Aurora kinase BAurkbRn01460656_m1[NM_024141.1](ncbi-n:NM_024141.1){#intr0030}Dual oxidase 2Duox2Rn01514628_m1NM_001106335.1Inner centromere proteinIncenpRn01478880_g1[NM_139326.2](ncbi-n:NM_139326.2){#intr0035}ProopiomelanocortinPomcRn00595020_m1[NM_022183](ncbi-n:NM_022183){#intr0040}Topoisomerase (DNA) II alphaTop2aRn00573347_m1  Normalizing Gene[NR_046239.1](ncbi-n:NR_046239.1){#intr0045}45S pre-ribosomal RNA18SRn03928990_g1[^2]

We used the same total RNA as used for microarrays. First-strand cDNA was synthesized from 250 ng DNAse treated total RNA using 250 ng random primers and SuperScript™ II Reverse Transcriptase (Invitrogen/Life Technologies, Grand Island, NY, USA) in a 20 μL reaction, as per the manufacturer's protocol. qPCR analysis was performed in an ABI 7500 Fast System instrument (Applied Biosystems, Foster City, CA, USA). In brief, a mixture was made with 1 μL cDNA template (diluted to 100 ng/L), 0.5 μL of each probe from the specific TaqMan assay (20X), 1 μL of a 2X TaqMan Fast Advanced master mix and 3 μL Nuclease-free water in 10 μL total volume per reaction, as indicated in the manufacturer's protocol. TaqMan PCR cycling conditions were set at 95 °C for 20 s for the first cycle and 3 s at 95 °C followed by 30 s at 60 °C for the remaining 40 cycles, as indicated in the manufacturer's protocol. All experimental samples were run in duplicate, along with two negative controls; a "no reverse transcriptase (-RT)" control, in which DNase-treated RNA samples were pooled and water was used in place of reverse transcriptase during the reverse transcription reaction, and a "no template control (NTC), " in which water was used in place of template cDNA during the real-time PCR reaction. 18S ribosomal RNA was used as the reference gene to normalize expression data. The results were analyzed using the ΔΔCt method of relative quantification [@bib0225].

2.9. Statistical analyses {#sec0055}
-------------------------

Significant differences in plasma levels of hormones in AA treated animals were determined using one-way analysis of variance (ANOVA) followed by a Tukey's Test. For qPCR a t-test was performed on normalized gene expression to evaluate whether the expressions were statistically different compared to controls (p \< 0.05).

For both plasma hormone levels and qPCR when data were not normally distributed, the Kruskal--Wallis non-parametric test was followed by the Mann-Whitney U-test. A *p*-value ≤0.05 was considered statistically significant. Statistical analyses were performed using Sigma Plot (SYSTAT, Chicago, IL, USA) and figures were plotted using Prism 5.0 (GraphPad Software Inc., San Diego CA).

3. Results {#sec0060}
==========

3.1. Phenotypic anchoring: measurement of plasma hormones in treated and control rats {#sec0065}
-------------------------------------------------------------------------------------

Changes in plasma hormone concentrations in pnd 35 rats occurred mainly in nocturnal animals of both sexes. Male rat plasma collected at night showed significant increases in T4, T3 and pituitary ACTH by 87%, 24.6% and 223%, respectively compared to controls. In females collected at night, plasma TSH was reduced by 44.7% and T4 and T3 were increased by 84.6% and 20.2%, respectively, compared to controls. The changes in T3 and T4 levels in female and male rats sampled at night closely matched each other ([Fig. 1](#fig0005){ref-type="fig"}). Prolactin was only decreased in male rats sampled in the morning with levels decreased by 76% (data not shown). Other hormones tested were not significantly altered in any of the animals.Fig. 1Plasma levels of thyroid hormones and TSH in animals collected in the morning and at night (n = 5 per group). (A, C, E) Animals sampled in the morning; (B, D, F) animals sampled at night with (A, B) TSH; (C, D) T3; and (E, F) T4. Box plots indicate the upper and lower percentile (10--90th) and the median values (horizontal black line within box). Whiskers represent the highest and lowest points. Different letters indicate significant differences among groups. CTRL (control group); AA (Acrylamide-treated group); MM (male morning); FM (female morning); MN (male night); FN (female night).Fig. 1

Interestingly, only night animals showed changes in genes related to thyroid hormone biosynthesis and function. Genes pertaining to this pathway that were changed in males sampled at night are shown in [Fig. 2](#fig0010){ref-type="fig"}. Fewer genes in this pathway were changed in females sampled at night.Fig. 2Changes in gene expression that were related to thyroid hormone generation and thyroid function in male rats sampled at night. Pathways were built by sub-networks enrichment analysis (p-value \>0.05; fold change \> ± 1.2; statistically analyzed by Fisher's Exact Test) using PathwayStudio™. Blue indicates down-regulation of gene expression; red, up-regulation; and yellow indicates the processes likely affected. Color intensity correlates with the degree of response. The abbreviations of the genes are listed in the abbreviations list.Fig. 2

3.2. Gene expression changes in male and female rats {#sec0070}
----------------------------------------------------

Microarray analysis was performed separately on thyroids of animals collected in the morning or at night. ANOVA results indicated a large number of differentially regulated genes for rats exposed to AA. Male rat thyroids collected at night exhibited 1800 altered genes (1157 up-regulated and 642 down-regulated). With an FDR correction of 10%, only one gene (solute carrier family 35, member B1 (Slc35b1) was significantly altered in this group. There were procedural issues for the microarrays for males collected in the morning and for that reason the results are not presented here.

Female thyroids sampled at night presented 2221 genes (1155 up-regulated and 1066 down-regulated), whereas female thyroids collected in the morning presented 2793 genes (854 up-regulated and 1939 down-regulated). Application of a FDR at 5% showed no altered genes. In order to get pathway information, we broadened the criteria to include genes that were altered with a p value \<0.05 and fold expression \> ±1.2 and an FDR was not applied. Changes in gene expression are shown in Table SI-1.

The differentially regulated transcripts were ordered according to their fold-expression levels in males sampled at night (MN) followed by their expression levels in females sampled at night (FN), and then females sampled in the morning (FM) (Fig SI-1), keeping the same order of genes. This evaluation showed that many genes were significantly altered in the same direction in both male and female samples collected at night, but some of these same genes were altered in different directions in females collected in the morning. A partial list of these common genes can be found in [Table 2](#tbl0010){ref-type="table"}.Table 2Partial list of transcripts from males and females collected at night that were most changed including those encoding processes involved with thyroid hormone generation, processing and protein transport, motor proteins, detoxifying enzymes, transcripts involved in oxidative stress, and checkpoint pathways involved in cancer.Table 2Probe NameGen bank AccessionGene SymbolGene NameFold Change\
(*p* *≤* *0.05*)MaleFemaleThyroid hormoneA_64_P076450[NM_139326](ncbi-n:NM_139326){#intr0050}PomcProopiomelanocor-tin18.46.3A_64_P155193[NM_021653](ncbi-n:NM_021653){#intr0055}Dio1Deiodinase, iodothyronine, type I1.41.6A_42_P625922[NM_012547](ncbi-n:NM_012547){#intr0060}Drd2Dopamine receptor5.22.4A_44_P238257[NM_053920](ncbi-n:NM_053920){#intr0065}Trip10Thyroid hormone receptor interactor 10−1.5−1.3Processing and protein transportA_43_P16457NM_001037208Creld2Cysteine-rich with EGF-like domains 22.22.1A_64_P056846[NM_012815](ncbi-n:NM_012815){#intr0070}GclcGlutamate-cysteine ligase, catalytic subunit2.01.4A_64_P021433NM_001007755SclySelenocysteine lyase1.71.3Motor proteinsA_42_P757258NM_001107609Kif20bKinesin family member 20B1.81.3A_64_P108200NM_001009645Kif22Kinesin family member 221.71.2A_64_P111749XM_001057533Kif2aKinesin family member 2A1.71.9A_44_P163018NM_001009619Nubp1Nucleotide binding Protein 11.31.2A_44_P463313[NM_017100](ncbi-n:NM_017100){#intr0075}Plk1polo-like kinase 11.51.3A_44_P213149NM_001107369MastlMicrotubule associated serine/threonine kinase-like2.31.6Detoxifying enzymes/Oxidative StressA_64_P137037[NM_017156](ncbi-n:NM_017156){#intr0080}Cyp2b12Cytochrome P450, family 2, subfamily b, polypeptide 121.42.0A_64_P004231NM_001159739Gsta5Glutathione S-transferase Yc2 subunit2.51.5A_42_P678430[NM_022303](ncbi-n:NM_022303){#intr0085}Card9Caspase recruitment domain family, member 91.61.4A_64_P119916[NM_024141](ncbi-n:NM_024141){#intr0090}Duox2Dual oxidase 21.71.2A_64_P095830[NM_152242](ncbi-n:NM_152242){#intr0095}Gpr56G protein-coupled receptor 561.61.3A_42_P636627[NM_017110](ncbi-n:NM_017110){#intr0100}CartptCART prepropeptide1.62.4A_64_P069374[NM_017247](ncbi-n:NM_017247){#intr0105}Scn10aSodium channel, voltage-gated, type X, alpha3.11.9A_64_P035564NM_001108682Tlr12Toll-like receptor 121.61.8Checkpoint pathways and cancerA_64_P012009NM_001106787Mov10L1Mov10L1, Moloney leukemia virus 10-like 1, homolog (mouse)3.22.4A_44_P478066NM_001106335IncenpInner centromere protein1.41.4A_64_P033214[XM_346406](ncbi-n:XM_346406){#intr0110}Top2aTopoisomerase (DNA) II alpha1.51.5A_43_P10723XM_001080736Bub1bBudding uninhibited by benzimidazoles 1 homolog, beta1.71.4A_44_P1045354[NM_199081](ncbi-n:NM_199081){#intr0115}Slc35b1Solute carrier family 35, member B11.91.3

These genes are involved in processes including, xenobiotic metabolism, motor proteins, oxidative stress, and cell cycle checkpoint pathways, among others. Genes that were commonly altered in females collected in the morning and at night are presented in [Table 3](#tbl0015){ref-type="table"}. Remarkably, females collected in the morning also showed a large group of altered genes that were not altered in animals collected at night. Some of these genes are in the same families as genes altered at night and their non-correspondence may be due to the use of different microarrays for these analyses. Thus, the best way to jointly analyze these data is at the pathway level rather than at the specific gene level.Table 3Common genes significantly altered by AA in females sampled in the morning (AM) and at night (PM).Table 3Fold Change (p \< 0.05)Probe NameGen bank AccessionGene SymbolGene NameAMPM*Up-regulated*A_44_P533786[NM_053749](ncbi-n:NM_053749){#intr0120}AurkbAurora kinase B2.81.4A_44_P461544NM_001009470Ccnb2Cyclin B22.81.5A_44_P534089[NM_171991](ncbi-n:NM_171991){#intr0125}Ccnb1Cyclin B12.71.4A_42_P535608NM_001107160Asf1bASF1 anti-silencing function 1 homolog B (S. cerevisiae)2.61.4A_44_P189375NM_001001719Fancd2Fanconi anemia, complementation group D22.61.5A_44_P381917[NM_133386](ncbi-n:NM_133386){#intr0130}Sphk1Sphingosine kinase 12.51.7A_44_P223446NM_001107873Mcm2Minichromosome maintenance complex component2.41.4A_44_P478066NM_001106335IncenpInner centromere protein2.31.4A_44_P213149NM_001107369MastlMicrotubule associated serine/threonine kinase-like2.31.6A_64_P075910NM_001101014Ajap1Adherens junction associated protein 12.21.6A_64_P129618NM_001017459Mdm1Mdm1 nuclear protein homolog (mouse)2.21.2A_42_P643574NM_001106795AaasAchalasia, adrenocortical insufficiency, alacrimia (Allgrove, triple-A)1.71.2A_42_P502590NM_001107424Slc7a6Solute carrier family 7 (cationic amino acid transporter, y+ system), member 61.61.2A_64_P097193XM_001072207Topbp1Topoisomerase (DNA) II binding protein 11.51.2*Down-regulated*A_64_P008477NM_001000247Olr325Olfactory receptor 325−1.4−1.2A_42_P463998[NM_031013](ncbi-n:NM_031013){#intr0135}Abcc6ATP-binding cassette, sub-family C (CFTR/MRP), member 6−1.5−2.0A_64_P029596NM_001102417Svs3bSeminal vesicle secretory protein 3B−1.6−3.0A_44_P302179XM_001070842Naip5NLR family, apoptosis inhibitory protein 5−1.6−1.4A_44_P612186NM_001107344MylipMyosin regulatory light chain interacting protein−1.6−1.2A_44_P279116XM_002726450Dyrk4Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4−1.6−1.3A_64_P083349[NM_021843](ncbi-n:NM_021843){#intr0140}KitlgKIT ligand−1.6−1.3A_64_P010648NM_001105822Ccl12Chemokine (C-C motif) ligand 12−1.7−1.4A_64_P008330NM_001000020Olr1454Olfactory receptor 1454−1.7−1.3A_44_P1000391NM_001106140Atp8b1ATPase, Class I, type 8B, member 1−1.8−1.2A_64_P050650[XM_344594](ncbi-n:XM_344594){#intr0145}Sox4SRY (sex determining region Y)-box 4−1.9−1.3A_64_P127823NM_001108629GgctGamma-glutamyl cyclotransferase−1.9−1.2A_44_P684740NM_001107279Pcdh17Protocadherin 17−2.3−1.4A_64_P008502NM_001109574Tmem169Transmembrane protein 169−2.7−1.5A_43_P12257[NM_022604](ncbi-n:NM_022604){#intr0150}Esm1Endothelial cell-specific molecule 1−2.9−1.6

3.3. Common alterations of the transcriptome for rats of both genders {#sec0075}
---------------------------------------------------------------------

The genes selected by ANOVA were used for SNEA. Several sub-networks were common to all of the animals tested ([Table 4](#tbl0020){ref-type="table"}). Common pathways altered in both males and females at the lowest p values (\<8.0E-07) included cell proliferation, cell differentiation, apoptosis, cell death, cell migration, cell growth, cell cycle, protein folding, and myogenesis, among others. The top 100 predicted pathways via SNEA for animals sampled at night males had a p value \<0.002 for males and \<0.009 for females (Table SI-2). However, it is clear from [Table 5](#tbl0025){ref-type="table"} that the top gene sets altered in females sampled at night were different from those altered in females in the morning.Table 4Partial list of common sub-networks significantly affected in the thyroid gland of male and female rats exposed to AA. Complete data are shown in Table SI-2.Table 4Sub-networksp-value (\<0.05)Gene Set SeedMale at nightFemale at nightFemale at morningCell proliferation8.3E-141.1E-109.4E-11Cell differentiation2.0E-111.9E-105.4E-10Apoptosis3.4E-109.2E-154.1E-13Cell death4.9E-107.6E-091.3E-07Cell migration6.3E-095.7E-061.2E-06Vascularization2.7E-081.7E-033.2E-07Cell growth5.0E-082.5E-086.1E-11Cell cycle9.2E-086.3E-089.1E-07Pregnancy7.3E-073.7E-032.3E-03Oxidative stress7.6E-078.6E-047.9E-06Cell survival1.7E-065.1E-051.7E-05Endocytosis2.3E-065.2E-044.5E-07Heart function4.6E-066.3E-036.9E-03Contraction1.4E-052.3E-034.9E-03G2/M transition1.7E-051.4E-052.6E-04Morphogenesis2.1E-051.9E-062.4E-03Ossification3.6E-051.2E-041.8E-02Inflammatory response6.2E-054.7E-034.9E-03Protein folding2.6E-041.0E-031.5E-02Myogenesis1.4E-048.6E-044.0E-04DNA replication5.0E-048.9E-042.8E-03Response to hypoxia9.8E-048.9E-035.0E-03Table 5Sub-networks that were significantly altered by AA in female rats sampled at night (FN) or in the morning (FM) (statistically tested by Fisher's Exact Test (p \< 0.05, data in order of lowest p-value).Table 5Gene Set Seedp-value (FN)p-value (FM)Mitosis8.05E-07NEEmbryonal development6.85E-06NEM phase4.61E-05NEKinetochore assembly5.01E-05NEMeiosis7.94E-05NEOncogenesis1.13E-04NEDNA replication checkpoint1.30E-04NEMacrophage differentiation1.67E-04NEG2 phase1.67E-04NEGenetic instability1.99E-04NEG2/M checkpoint2.60E-04NERegeneration2.83E-04NEResponse to stress3.52E-04NEMitotic entry4.76E-04NEMitotic checkpoint4.87E-04NEMuscle development4.98E-04NEFibroblast accumulation5.22E-04NEMuscle regeneration5.41E-04NEER-associated protein catabolism6.76E-04NEMicrotubule cytoskeleton assembly7.21E-04NEErythrocyte differentiation7.79E-04NENerve maturation8.50E-04NEXenobiotic metabolism8.61E-04NEMitotic spindle assembly9.06E-04NEChromosome condensation1.03E-03NECell adhesionNE1.77E-05Mitochondrial damageNE2.81E-05Regulation of cell sizeNE5.23E-05Muscle cell differentiationNE9.85E-05Kidney functionNE1.19E-04Glial cell responseNE1.40E-04Cell-cell adhesionNE1.57E-04Adipocyte differentiationNE1.61E-04Wound healingNE4.84E-04SMC proliferationNE5.90E-04Neuron apoptosisNE6.80E-04LuteinizationNE8.26E-04G1 phaseNE8.44E-04SenescenceNE8.79E-04Actin organizationNE9.21E-04Secretory pathwayNE1.14E-03Endothelial cell functionNE1.15E-03Endothelial cell proliferationNE1.22E-03Myocyte proliferationNE1.26E-03ColonizationNE1.28E-03ArteriogenesisNE1.39E-03Embryo implantationNE1.40E-03Biomineral formationNE1.44E-03Autophagic cell deathNE1.65E-03Endomitotic cell cycleNE1.74E-03[^3]

When both genders were analyzed together for this time point, the top 12 common pathways altered were cell death, apoptosis, protein folding, kinetochore assembly, decidualization, pregnancy, colorectal motility, muscle development, eating behavior, response to heat shock, oocyte development and heart function (p value \<0.0008) (Table SI-3A). When females from the night and morning sampling times were analyzed together to find common pathways, the top pathways included DNA replication, apoptosis, cell growth and cell proliferation, among others (Table SI-3B).

The lists of genes from the microarray analysis were also subjected to a non-parametric statistical analysis, GSEA, which provided additional pathway information. An analysis for pathways for all three groups yielded 10 cellular processes that were commonly altered with DNA replication heading the list ([Table 6](#tbl0030){ref-type="table"}). When considering only animals sampled at night, there were 20 common pathways, including INO80Chromatin Remodeling, TRRAP/Tip60Chromatin Remodeling, mRNA Transcription and Processing, Double Strand DNA Homologous Repair, cell cycle and DNA replication, among others (Table SI-4A and 4B). There was good concordance between the pathways selected via SNEA and the GSEA.Table 6Common pathways identified by GSEA in the thyroid gland of male and female rats exposed to AA.Table 6Gene Set Category: Ariadne Cell Process PathwaysMale at nightFemale at nightFemale at morningMedian changep-valueMedian changep-valueMedian changep-valueDNA replication1.30.011.101.10Histone and DNA methylation1.20.021.10NE0.01Histone phosphorylation1.101.101.10Direct DNA repair1.10.021.101.10.01Single-strand mismatch DNA repair1.201.101.10Double strand DNA homologous repair1.201.101.10Single-strand base excision DNA repair1.20.011.101.10Cell cycle1.201.101.10Actin cytoskeleton assembly1.10NE0.021.20.01Tight junction assembly (Occludin)1.201.10.03NE0.01[^4]

Selected pathways graphically show similarities between males and females sampled at night ([Fig. 3](#fig0015){ref-type="fig"}, [Fig. 4](#fig0020){ref-type="fig"}, [Fig. 5](#fig0025){ref-type="fig"} ).Fig. 3Alterations in gene expression related to (A--B) spindle assembly and (C--D) kinetochore assembly. These pathways were built using sub-networks enrichment analysis (SNEA) (p-value \> 0.05; fold change \>± 1.2; by Fisher's Exact Test) using PathwayStudio™. (A, C) Male rats sampled at night; and (B, D) female rats sampled at night. Blue, down-regulated genes; red, up-regulated genes. Abbreviations for gene names are in the abbreviation list.Fig. 3Fig. 4Alterations in gene expression related to reactive oxygen species (A-B) (ROS) and (C-D) microtubule cytoskeleton assembly. These pathways were built using sub-networks enrichment analysis (SNEA) (p-value \> 0.05; fold change \>± 1.2; by Fisher's Exact Test) using PathwayStudio™. (A, C) Male rats sampled at night; and (B, D) female rats sampled at night. Blue, down-regulated genes; red, up-regulated genes. Abbreviations for gene names are in the abbreviation list.Fig. 4Fig. 5Genes altered by AA exposure of rats that relate to (A-B) DNA replication and (C-D) DNA repair. These pathways were built using sub-networks enrichment analysis (p-value \> 0.05; fold change \>± 1.2; by Fisher's Exact Test) using PathwayStudio™. (A, C) Male rats sampled at night; and (B, D) female rats sampled at night. Blue, down-regulated genes; and red, up-regulated genes. Abbreviations for gene names are in the abbreviation list.Fig. 5

3.4. Diurnal changes in female rats sampled either at night or in the morning. {#sec0080}
------------------------------------------------------------------------------

Diurnal changes in gene expression could only be observed in female rats, since we had issues with the microarrays for male rats. We observed many more changes in pathways in female rats sampled at night than those sampled in the morning (Table SI-4B and 4C). While both groups showed changes in similar repair mechanisms including DNA repair, protein degradation and recycling, chromatin remodeling, and the immune system; there were many more entities present in the affected pathways in animals sampled at night than those sampled in the morning. However, among the top pathways with the lowest P values (\<0.01) by GSEA, 15 were only altered in females collected at night which involved methylation of histones and DNA, chromatin remodeling, mRNA and rRNA transcription and processing, tight junction assembly, and immune function, such as peptide antigen and complement pathways. One pathway was shared by both morning and night animals, which involved ubiquitin-dependent protein degradation, and 1 pathway was altered only in females collected in the morning and this involved actin cytoskeleton assembly ([Table 7](#tbl0035){ref-type="table"}).Table 7Differences in pathways determined by GSEA in female rats sampled at night or in the morning (p \< 0.05, data ordered by lowest p-value).Table 7FemalesGene Set Category:NightMorningAriadne Cell Process PathwaysMedian changep-valueMedian changep-valueHistone and DNA methylation1.10NENESWI/SNF BRG1/BAF Chromatin remodeling1.10NENESWI/SNF BRG1/PBAF Chromatin remodeling1.10NENENURD Chromatin remodeling1.10NENENURF Chromatin remodeling1.10NENECHRAC Chromatin remodeling1.10NENESRCAP Chromatin remodeling1.10NENEPresentation of endogenous peptide antigen1.10NENEmRNA Transcription and processing1.10NENErRNA Transcription and processing1.10NENEHistones sumoylation1.10NENESingle-strand nucleotide excision DNA repair1.17.5E-03NENESWI/SNF BRM/BAF Chromatin remodeling1.12.0E-02NENETight junction assembly (Occludin)1.12.8E-02NENEClassical complement pathway−1.24.0E-02NENEUbiquitin-dependent protein degradation1.14.2E-021.104.9E-03Actin cytoskeleton assemblyNENE1.151.0E-02[^5]

3.5. Validation of gene expression changes by qPCR {#sec0085}
--------------------------------------------------

Genes implicated in cell cycle checkpoint pathways were investigated due to their presence in many of the sub-networks. There is good concordance between microarray and qRT-PCR ([Table 8](#tbl0040){ref-type="table"}). Only changes in the mRNA for *card 9* and TPO were significantly altered (p \< 0.05) in the qPCR assay when compared to controls but the fold differences observed for microarray and qPCR for these genes were similar. qPCR is an exponential expansion of the data and small pipetting errors sometimes lead to non-significant differences being observed. We probably needed a higher "n" for statistical significance.Table 8Comparison of fold changes in mRNA steady state levels obtained from microarray and qPCR analyses for selected genes involved in cell checkpoint pathways and oxidative stress for male and female rats sampled in the morning and at night.Table 8(A) Morning groupFemaleGene SymbolsMicroarrayqPCRAurkb2.83[a](#tblfn0010){ref-type="table-fn"}2.52Duox2−1.73[a](#tblfn0010){ref-type="table-fn"}−1.30Incenp2.33[a](#tblfn0010){ref-type="table-fn"}1.85Pomc−1.50[a](#tblfn0010){ref-type="table-fn"}−1.05Top2a3.27[a](#tblfn0010){ref-type="table-fn"}3.44(B) Night groupMaleFemaleGene SymbolsMicroarraysqPCRMicroarraysqPCRCard91.62[a](#tblfn0010){ref-type="table-fn"}1.64[\*\*](#tblfn0015){ref-type="table-fn"}1.421.20Ddit 42.63[a](#tblfn0010){ref-type="table-fn"}1.421.211.02Drd25.17[a](#tblfn0010){ref-type="table-fn"}5.182.423.58Tpo1.59[a](#tblfn0010){ref-type="table-fn"}1.90[\*\*](#tblfn0015){ref-type="table-fn"}1.181.18Tnfs131.63[a](#tblfn0010){ref-type="table-fn"}1.601.341.1[^6][^7][^8]

4. Discussion {#sec0090}
=============

AA is known to produce thyroid gland follicular cell tumors and mammary gland fibroadenomas in Wistar rats. AA has been classified as a genotoxic chemical because it can alkylate DNA and cause chromosome breaks and rearrangements (clastogenic mode of action), but only at high concentrations. In the current experiment, glycidamide adducts were measured from AA [@bib0115]. Cyp2E1 is moderately expressed in the thyroid [@bib0020]. But, the active concentrations of glycidamide would have been quite low since we used a relatively low concentration of AA in a chronic exposure scenario. We tested the hypothesis that AA would alter gene expression and physiological endpoints in Wistar rats at night when they are active more so than in the daytime, when rats are sleeping. AA and glycidamide have very short biological half-lives so we thought the evening measurement would be a more sensitive indicator of AA immediate effects in these neonatal rats because AA and glycidamide would still be present in the circulation. While the overall gene expression changes observed clearly involve DNA damage and repair, there were also changes involving oxidative stress, cellular motility, motor proteins such as the kinesin-related proteins, and kinases, all of which may be causally related to genotoxicity and oncogenicity.

4.1. Phenotypic anchoring {#sec0095}
-------------------------

A separate cohort of the same animals was allowed to continue on the same regimen for 2 years [@bib0255]. At the end of the two-year period, histopathology indicated tumors of the mammary gland (fibroadenomas) in females and thyroid follicular cell tumors in both sexes. No other increase of tumors was found. Hemoglobin adducts of acrylamide and glycidamide were measured over several timepoints throughout the 2 years and these showed dose and time response [@bib0115], confirming the exposures. We did not check for DNA adducts, but in other studies, these types of exposures have been shown to induce DNA adducts [@bib0370]. In addition, other non-neoplastic changes were observed including sciatic nerve nephropathy, spinal cord degeneration and hind limb myopathy [@bib0255]. Previous studies with rats have shown similar thyroid follicular cell neoplasms [@bib0010], [@bib0130].

The only phenotypic endpoints we measured in the pnd 35 animals were plasma hormones. Thyroid hormones were altered only in animals sacrificed at night with both males and females showing increased plasma T3 and T4, and only females showing depressed TSH. Normally one would expect that disruption of the HPT axis in rodents in a manner that induces thyroid carcinogenesis would be through increased TSH secretion that provides growth stimulus to the thyroid gland [@bib0040]. Our results suggest that the changes in T3 and T4 were primary as opposed to secondary due to an elevation in TSH. The decreased TSH in females might reflect negative feedback suppression due to the elevated thyroid hormones.

In a study with male adult Fischer 344 rats exposed to three concentrations of AA (2.5 mg/kg/d; 10 mg/kg/d and 50 mg/kg/d) in their drinking water for 14 days and sacrificed presumably during the day, only the highest dose of AA showed a significant decrease in T4 while T3 levels showed a non-significant increasing trend [@bib0025]. These authors concluded that AA did not affect hormone production in the animals. But, critical differences exist with our study. Animals collected in the day in our study also did not show any specific effects in the plasma, but animals collected at night, did, as discussed above.

Several genes associated with thyroid function were altered in rats in the current study that point to dysregulation of hormone production. The altered genes included neuropeptide Y (NPY), solute carrier family 5 (sodium iodide symporter), member 5 (SLC5A5), iodotyrosine deiodinase (IYD) and thyroid stimulating hormone receptor (TSHR) (Table SI-1). Sub-network analysis suggested that thyroid hormone generation and thyroid function were altered in males ([Fig. 2](#fig0010){ref-type="fig"} and Table SI-2).

4.2. Commonalities and differences in gene expression changes in males and females sampled at night and in the morning {#sec0100}
----------------------------------------------------------------------------------------------------------------------

Consistent with the known effects of AA, genes associated with spindle and kinetochore assemblies were altered ([Fig. 3](#fig0015){ref-type="fig"}). Both male and female night animals showed alteration of many elements in these pathways, including three kinesins, Kif20b, Kif22, and Kif2a. Kinesins are microtubule-associated motor proteins, which are essential components for intracellular transport and cell division [@bib0285]. There are 45 members of this superclass of proteins in mammals and their main attribute is having a microtubule binding domain and an ATPase domain. These proteins can walk along microtubules to deliver cargo to the appropriate places. Kinesins have been associated with cancer. For example, over expression of Kif2a has been associated with poor outcome for colorectal cancer [@bib0105].

Kinesins have been demonstrated to be direct targets for AA and glycidamide [@bib0135], [@bib0265], [@bib0330]. While different kinesins were studied than the three upregulated in the current study, the fact that the activity of KIFC5A and KRP2, representative of two different kinesin families, could be inhibited by relatively low concentrations of AA or glycidamide (range 100--5 mM for 60--80% inhibition), suggests that the entire family may be vulnerable [@bib0330], leading to cell division defects and potential carcinogenicity.

Interestingly, pathways involved with oxidative stress were also prominent for night animals ([Fig. 4](#fig0020){ref-type="fig"}). While ROS was not directly measured in this study, steady state levels of mRNAs encoding proteins involved in this process were up-regulated. The overall pathway for ROS was up-regulated in both males and females sampled at night but down-regulated in females sampled in the morning. ROS generation by acrylamide has been observed in other studies [@bib0160], [@bib0230].

A similar pattern is seen for microtubule cytoskeleton assembly showing up-regulation of this process in night animals but an overall down-regulation in females sampled in the morning. Interestingly, night animals showed down-regulation of genes involved in muscle development suggesting that energy was diverted toward repair and detoxification and away from general anabolic metabolism (data not shown).

DNA repair, DNA replication, cell proliferation, checkpoint pathways, and apoptosis were altered by the low chronic dose of AA employed in the current study. [Fig. 5](#fig0025){ref-type="fig"} illustrates some of the entities that were common for DNA replication and DNA repair in males and females sampled at night ([Fig. 5](#fig0025){ref-type="fig"}). As prognostic markers of cancer, transcripts involved in key checkpoint pathways were altered, including inner centromere protein (Incenp), topoisomerase (DNA) II alpha (Top2A) and budding uninhibited by benzimidazoles 1 homolog, beta (*Saccharomyces cerevisiae*) (Bub1B), among others ([Table 2](#tbl0010){ref-type="table"}). Transcripts involved in neurotoxicity also were affected, for example dopamine receptor D2 (Drd2), which was increased by 5.2 (p = 0.018) fold in males and by 2.4 (p = 0.05) fold in females collected at night. The role of dopamine in peripheral tissues is an area of current interest [@bib0320]. Our data is consistent with the observation that exposure to acrylamide inhibited the uptake of dopamine into striatal synaptic vesicles of rats [@bib0005], [@bib0235].

AA is a type-2 alkene, which is a soft electrophile that reacts preferentially with nucleophilic cysteine thiolate sites of proteins, as can be found in catalytic triads [@bib0240]. However, a low but consistent reaction with the N-terminal Val group of hemoglobin has also been observed for AA and this has been used as an effective bioassay for acrylamide exposure [@bib0115], [@bib0120], [@bib0290]. *In vivo*, AA is metabolized by CYP 2E1 to glycidamide (an epoxide), which is very reactive toward nucleophiles and has been implicated in adduct formation for hemoglobin and nucleic acids [@bib0115], [@bib0265].

Glycidamide is also a potential source of oxidative stress. AA is converted to glycidamide, with rates varying from organ to organ [@bib0185]. AA can also bind to glutathione [@bib0125], [@bib0145], [@bib0245], [@bib0350], which normally is at high intracellular concentrations between 0.1 mM and 15 mM [@bib0065]. While most cellular proteins would be protected by the high GSH, the intracellular concentrations can vary depending on the location, with the lowest intracellular ratio of GSH-GSSG measured in the rough endoplasmic reticulum [@bib0065]. Modulation of GSH levels by AA has been demonstrated in Syrian Hamster Embryo (SHE) cells and is an essential occurrence for cell transformation [@bib0195].

Because AA effectively alkylates Cys residues, a low ratio of GSH:GSSG would promote alkylation of proteins, which would be influenced by active drinking of AA laced water. Both cysteine and glutathione were protective of AA induced malformation in frogs [@bib0315]. Reactivity toward Cys suggests vulnerabilities. If proteins with active site Cys residues were adducted, this could result in enzyme inactivation. The system would likely respond by making more mRNA for inactivated proteins. Interestingly, in our study, we identified increased levels of mRNAs for proteins that are known to be cysteine rich and that may contain Cys residues in their active sites, including cysteine-rich with EGF-like domains 2 (Creld2), glutamate-cysteine ligase (Gclc) catalytic subunit, and selenocysteine lyase (Scly), which were increased by 2.2 fold and 2.1 fold; by 2.0 and 1.4; and by 1.7 and 1.3 in male and female rats at night, respectively ([Table 2](#tbl0010){ref-type="table"}). Creld2 has been proposed as a novel endoplasmic reticulum stress-inducible gene, associated with folding, processing and protein transport [@bib0300]. Scly is a selenoprotein involved in cancer with its main function being protection against an excess of ROS [@bib0030], [@bib0340]. Gclc controls synthesis of GSH, the main antioxidant in the cell [@bib0045], [@bib0070], [@bib0210].

It is useful to consider a model that includes adaptive/compensatory gene expression changes as protective action against damage by low concentrations of AA. With chronic exposure, the compensatory pathways may not fully contain cellular damage, unleashing a second line of defense, for example up-regulation of apoptotic processes. At this stage of cellular assault, one would expect to see additional pathways altered including those involving structural proteins within the cell, since caspases activated via apoptosis can cut spectrin and other cellular scaffold proteins [@bib0375]. Only at higher levels of cellular damage, caused by the conversion of AA to glycidamide, would covalent adducts be seen with proteins and/or DNA, unleashing DNA repair and disturbing cell cycle regulation and check point pathways [@bib0050].

Dose-response relationships between the formation of tumors in thyroid tissues and genotoxic events suggest that other mechanisms in addition to genotoxicity might be involved in tumor formation in the thyroid at low concentrations of AA [@bib0075], for example through stimulation of thyroid cell proliferation by an alternate mechanism. The evidence that hormones may be involved actually comes from studies using relatively high doses of AA, 10--50 mg/Kg bw/d. At these high concentrations of AA, serum LH levels were significantly increased, while FSH, testosterone and prolactin, were significantly decreased in chronically dosed male rats [@bib0035]. At lower doses of AA (2--15 mg/Kg bw/d range; 2--7 day exposure), a slight increase in T4 and a decrease of TSH levels were previously reported [@bib0180], which are in agreement with hormonal changes seen in our study.

Rats are nocturnal animals and sleep during the day from 6 AM to 6 PM [@bib0150], [@bib0355]. The sampling regimen was designed to sample rats at night when they were actively drinking water laced with AA and compare them to quiescent animals sampled in the morning. In each case, the sampling occurred several hours into each phase, at 10 PM or 10 AM. While all animals showed alterations in genes related to DNA damage, there were additional altered pathways that appeared mainly in the night groups, suggesting that these were stimulated by newly introduced AA. These pathways were related with reactive oxygen species, oxidative stress, detoxification systems, energy production and metabolism.

The commonality among all of the AA dosed animals suggests DNA damage, cell damage and cell death as the primary, long-term effects caused by chronic AA exposure. These findings are consistent with other studies that point to DNA damage and tumorigenesis [@bib0055], [@bib0085], [@bib0130], [@bib0140], [@bib0190], [@bib0205], [@bib0250], [@bib0270], [@bib0305], [@bib0310].

These data bear directly on the regulatory classification of AA as a genotoxic carcinogen. In regulatory schemes AA risk is quantitated as that of a genotoxic carcinogen [@bib0090], [@bib0100]. However, at low and intermittent doses, tumorigenesis appears to be consecutive to AA targeting key cellular proteins and their functions leading to oxidative stress and to thyroid hormone changes, rather than genotoxicity.
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